The Role of Cancer Cell Bioenergetics in Dormancy and Drug Resistance

Overview

Journal Cancer Metastasis Rev

Specialty Oncology

Date 2023 Jan 25

PMID 36696004

Authors

Steven Tau

Todd W Miller

Affiliations

Soon will be listed here.

Abstract

While anti-cancer drug treatments are often effective for the clinical management of cancer, these treatments frequently leave behind drug-tolerant persister cancer cells that can ultimately give rise to recurrent disease. Such persistent cancer cells can lie dormant for extended periods of time, going undetected by conventional clinical means. Understanding the mechanisms that such dormant cancer cells use to survive, and the mechanisms that drive emergence from dormancy, is critical to the development of improved therapeutic strategies to prevent and manage disease recurrence. Cancer cells often exhibit metabolic alterations compared to their non-transformed counterparts. An emerging body of evidence supports the notion that dormant cancer cells also have unique metabolic adaptations that may offer therapeutically targetable vulnerabilities. Herein, we review mechanisms through which cancer cells metabolically adapt to persist during drug treatments and develop drug resistance. We also highlight emerging therapeutic strategies to target dormant cancer cells via their metabolic features.

Citing Articles

The emerging role of circular RNAs in cisplatin resistance in ovarian cancer: From molecular mechanism to future potential.

Malek Mohammadi M, Rismanchi H, Esmailzadeh S, Farahani A, Hedayati N, Alimohammadi M Noncoding RNA Res. 2024; 9(4):1280-1291.

PMID: 39040815 PMC: 11261309. DOI: 10.1016/j.ncrna.2024.05.005.

C Tracer Analysis and Metabolomics in Dormant Cancer Cells.

Altea-Manzano P, Fendt S, Vera-Ramirez L Methods Mol Biol. 2024; 2811:195-206.

PMID: 39037660 DOI: 10.1007/978-1-0716-3882-8_15.

Resistance to 2-Hydroxy-Flutamide in Prostate Cancer Cells Is Associated with the Downregulation of Phosphatidylcholine Biosynthesis and Epigenetic Modifications.

Mora-Rodriguez J, Sanchez B, Sebastian-Martin A, Diaz-Yuste A, Sanchez-Chapado M, Palacin A Int J Mol Sci. 2023; 24(21).

PMID: 37958610 PMC: 10650717. DOI: 10.3390/ijms242115626.

Cancer Bioenergetics and Tumor Microenvironments-Enhancing Chemotherapeutics and Targeting Resistant Niches through Nanosystems.

Farhana A, Alsrhani A, Khan Y, Rasheed Z Cancers (Basel). 2023; 15(15).

PMID: 37568652 PMC: 10416858. DOI: 10.3390/cancers15153836.

Circular RNAs in gynecologic cancers: mechanisms and implications for chemotherapy resistance.

Qin M, Zhang C, Li Y Front Pharmacol. 2023; 14:1194719.

PMID: 37361215 PMC: 10285541. DOI: 10.3389/fphar.2023.1194719.

References

Lee K, Giltnane J, Balko J, Schwarz L, Guerrero-Zotano A, Hutchinson K . MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation. Cell Metab. 2017; 26(4):633-647.e7. PMC: 5650077. DOI: 10.1016/j.cmet.2017.09.009. View

Ladanyi A, Mukherjee A, Kenny H, Johnson A, Mitra A, Sundaresan S . Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis. Oncogene. 2018; 37(17):2285-2301. PMC: 5920730. DOI: 10.1038/s41388-017-0093-z. View

Camarda R, Zhou A, Kohnz R, Balakrishnan S, Mahieu C, Anderton B . Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer. Nat Med. 2016; 22(4):427-32. PMC: 4892846. DOI: 10.1038/nm.4055. View

Madak-Erdogan Z, Band S, Zhao Y, Smith B, Kulkoyluoglu-Cotul E, Zuo Q . Free Fatty Acids Rewire Cancer Metabolism in Obesity-Associated Breast Cancer via Estrogen Receptor and mTOR Signaling. Cancer Res. 2019; 79(10):2494-2510. DOI: 10.1158/0008-5472.CAN-18-2849. View

Viale A, Pettazzoni P, Lyssiotis C, Ying H, Sanchez N, Marchesini M . Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature. 2014; 514(7524):628-32. PMC: 4376130. DOI: 10.1038/nature13611. View

Zaugg K, Yao Y, Reilly P, Kannan K, Kiarash R, Mason J . Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. Genes Dev. 2011; 25(10):1041-51. PMC: 3093120. DOI: 10.1101/gad.1987211. View

Pike L, Smift A, Croteau N, Ferrick D, Wu M . Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells. Biochim Biophys Acta. 2011; 1807(6):726-34. DOI: 10.1016/j.bbabio.2010.10.022. View

Pardee T, Luther S, Buyse M, Powell B, Cortes J . Devimistat in combination with high dose cytarabine and mitoxantrone compared with high dose cytarabine and mitoxantrone in older patients with relapsed/refractory acute myeloid leukemia: ARMADA 2000 Phase III study. Future Oncol. 2019; 15(28):3197-3208. DOI: 10.2217/fon-2019-0201. View

Flynn A, Calhoun B, Sharma A, Chang J, Almasan A, Schiemann W . Autophagy inhibition elicits emergence from metastatic dormancy by inducing and stabilizing Pfkfb3 expression. Nat Commun. 2019; 10(1):3668. PMC: 6694140. DOI: 10.1038/s41467-019-11640-9. View

10.

Kunimasa K, Nagano T, Shimono Y, Dokuni R, Kiriu T, Tokunaga S . Glucose metabolism-targeted therapy and withaferin A are effective for epidermal growth factor receptor tyrosine kinase inhibitor-induced drug-tolerant persisters. Cancer Sci. 2017; 108(7):1368-1377. PMC: 5497794. DOI: 10.1111/cas.13266. View

11.

Naik P, Mukhopadhyay S, Praharaj P, Bhol C, Panigrahi D, Mahapatra K . Secretory clusterin promotes oral cancer cell survival via inhibiting apoptosis by activation of autophagy in AMPK/mTOR/ULK1 dependent pathway. Life Sci. 2020; 264:118722. DOI: 10.1016/j.lfs.2020.118722. View

12.

Sharon D, Cathelin S, Mirali S, Di Trani J, Yanofsky D, Keon K . Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response. Sci Transl Med. 2019; 11(516). DOI: 10.1126/scitranslmed.aax2863. View

13.

Shen S, Faouzi S, Souquere S, Roy S, Routier E, Libenciuc C . Melanoma Persister Cells Are Tolerant to BRAF/MEK Inhibitors via ACOX1-Mediated Fatty Acid Oxidation. Cell Rep. 2020; 33(8):108421. DOI: 10.1016/j.celrep.2020.108421. View

14.

Park J, Vithayathil S, Kumar S, Sung P, Dobrolecki L, Putluri V . Fatty Acid Oxidation-Driven Src Links Mitochondrial Energy Reprogramming and Oncogenic Properties in Triple-Negative Breast Cancer. Cell Rep. 2016; 14(9):2154-2165. PMC: 4809061. DOI: 10.1016/j.celrep.2016.02.004. View

15.

Zhang X, Fryknas M, Hernlund E, Fayad W, De Milito A, Olofsson M . Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments. Nat Commun. 2014; 5:3295. PMC: 3929804. DOI: 10.1038/ncomms4295. View

16.

Vyas A, Harbison R, Faden D, Kubik M, Palmer D, Zhang Q . Recurrent Human Papillomavirus-Related Head and Neck Cancer Undergoes Metabolic Reprogramming and Is Driven by Oxidative Phosphorylation. Clin Cancer Res. 2021; 27(22):6250-6264. PMC: 8611487. DOI: 10.1158/1078-0432.CCR-20-4789. View

17.

You B, Xia T, Gu M, Zhang Z, Zhang Q, Shen J . AMPK-mTOR-Mediated Activation of Autophagy Promotes Formation of Dormant Polyploid Giant Cancer Cells. Cancer Res. 2021; 82(5):846-858. PMC: 9359740. DOI: 10.1158/0008-5472.CAN-21-2342. View

18.

Rusu P, Shao C, Neuerburg A, Acikgoz A, Wu Y, Zou P . GPD1 Specifically Marks Dormant Glioma Stem Cells with a Distinct Metabolic Profile. Cell Stem Cell. 2019; 25(2):241-257.e8. DOI: 10.1016/j.stem.2019.06.004. View

19.

Tsvetkov P, Detappe A, Cai K, Keys H, Brune Z, Ying W . Mitochondrial metabolism promotes adaptation to proteotoxic stress. Nat Chem Biol. 2019; 15(7):681-689. PMC: 8183600. DOI: 10.1038/s41589-019-0291-9. View

20.

Roesch A, Vultur A, Bogeski I, Wang H, Zimmermann K, Speicher D . Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell. 2013; 23(6):811-25. PMC: 3810180. DOI: 10.1016/j.ccr.2013.05.003. View